Skip to main content

Table 2 Summary comparison of VMAT and HT plans

From: Evaluation of volumetric modulated arc therapy for postmastectomy treatment

Structure/Item Metric VMAT HT p-value
PTV DV95% (Gy) 49.3 ± 0.1 49.8 ± 0.1 <0.001
DHI 0.147 ± 0.009 0.096 ± 0.005 <0.001
CI 0.778 ± 0.008 0.719 ± 0.008 <0.001
TCP 99.8 ± 0.2 100 ± 0.0 0.002
Total lung V5Gy (%) 66.2 ± 3.1 89.8 ± 1.4 <0.001
V20Gy (%) 16.3 ± 0.2 15.0 ± 0.3 <0.001
NTCP (%) 0.3 ± 0.1 0.6 ± 0.1 0.06
SCCP (%) 5.3 ± 0.1 6.1 ± 0.0** <0.001
Ipsilateral lung V5Gy (%) 96.9 ± 1.3 99.3 ± 0.5 0.06
V20Gy (%) 32.3 ± 0.8 29.9 ± 1.0 <0.001
Contralateral lung V5Gy (%) 37.8 ± 4.9 81.7 ± 2.5 <0.001
Heart* V15Gy (%) 26.0 ± 1.9 28.2 ± 2.6 0.4
Dmean (Gy) 12.9 ± 0.5 14.4 ± 0.6 0.04
Dmax (Gy) 42.2 ± 1.6 38.3 ± 1.3 <0.001
NTCP (%) 1.3 ± 0.2 0.9 ± 0.1 0.008
Contralateral breast Mean dose (Gy) 1.5 ± 0.1 1.8 ± 0.1 <0.001
SCCP (%) 1.0 ± 0.0** 1.2 ± 0.0** <0.001
Non-specific normal tissue Mean dose (Gy) 7.0 ± 0.2 11.1 ± 0.4 <0.001
SCCP (%) 0.7 ± 0.0 0.9 ± 0.0** <0.001
Efficiency Delivery time (s) 128.6 ± 2.8 382.4 ± 10.9 <0.001
  1. Values shown are averages of the 15 patients (± 1σ) with the exception of the heart.
  2. *Patients with right-side mastectomy excluded.
  3. **Standard deviation of the mean < 0.05.
  4. Abbreviations: PTV planning target volume, DHI dose homogeneity index (ideal = 0), CI conformity index (ideal = 1), TCP tumor control probability, NTCP normal tissue complication probability, SCCP secondary cancer complication probability.